Post registration observational program for patients with locally recurrent or metastatic breast cancer who receive bevacizumab (Avastin) in combination with paclitaxel for the first-line treatment

Trial Profile

Post registration observational program for patients with locally recurrent or metastatic breast cancer who receive bevacizumab (Avastin) in combination with paclitaxel for the first-line treatment

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms AVATAX
  • Sponsors Roche
  • Most Recent Events

    • 28 Nov 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Jul 2010 Planned end date changed from 1 Jun 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 15 Jul 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health)(NCT01156961).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top